TY - JOUR
T1 - Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients
AU - Emanuel, Robyn M
AU - Dueck, Amylou C
AU - Geyer, Holly Lynn
AU - Kiladjian, Jean-Jacques
AU - Slot, Stefanie
AU - Zweegman, Sonja
AU - te Boekhorst, Peter
AU - Commandeur, Suzan
AU - Schouten, Harry C
AU - Sackmann, Federico
AU - Fuentes, Ana Kerguelen
AU - Hernandez, Dolores
AU - Pahl, Heike L
AU - Griesshammer, Martin
AU - Stegelmann, Frank
AU - Doehner, Konstanze
AU - Lehmann, Thomas
AU - Bonatz, Karin
AU - Reiter, Andreas
AU - Boyer, Francoise
AU - Etienne, Gabriel
AU - Ianotto, Jean-Christophe
AU - Ranta, Dana
AU - Roy, Lydia
AU - Cahn, Jean-Yves
AU - Harrison, Claire N
AU - Radia, Deepti H
AU - Muxi, Pablo J
AU - Maldonado, Norman I
AU - Besses, Carlos
AU - Cervantes, Francisco
AU - Johansson, Peter
AU - Barbui, Tiziano
AU - Barosi, Giovanni
AU - Vannucchi, Alessandro M
AU - Passamonti, Francesco
AU - Andreasson, Bjorn
AU - Ferarri, Maria L
AU - Rambaldi, Alessandro
AU - Birgegard, Gunnar
AU - Xiao, Zhijian
AU - Xu, Zefeng
AU - Zhang, Yue
AU - Sun, Xiujuan
AU - Xu, Junqing
AU - Zhang, Peihong
AU - Gale, Robert Peter
AU - Tefferi, Ayalew
AU - Mesa, Ruben A
PY - 2012/11/16
Y1 - 2012/11/16
N2 - Abstract 1726 BackgroundWe previously reported that symptom burden among persons with ET and PV can be severe and adversely affect QOL. The presence of severe symptoms is linked to poor prognosis. There is considerable inter-subject heterogeneity regarding which symptoms are present in which subjects. No studies have empirically evaluated whether disease characteristics can be grouped in related symptom clusters. Using our previously validated 18 item Myeloproliferative Neoplasm Assessment Form (MPN-SAF) (Blood 2011;118:401-408) given in conjunction with the 9 item Brief Fatigue Inventory (BFI) (Cancer 1999;85:1186-1196), we sought to evaluate symptom burden by means of cluster analysis. MethodsData was collected from an international cohort of subjects with MPNs including demographics, disease features and the completed BFI and MPN-SAF instruments. Surveyed symptoms included fatigue, early satiety, abdominal pain and discomfort, inactivity, headaches, concentration, dizziness, extremity tingling, insomnia, sexual difficulties, mood changes, cough, night sweats, pruritus, bone pain and fever on a 0 (absent) to 10 (worst-imaginable) scale. Development of symptom clusters was based on consideration of r-squared in hierarchical clustering using Ward linkage. Final cluster assignment was based on the nonhierarchical k-means method. Comparisons between symptom clusters were based on ANOVA and chi-squared tests. ResultsSubject Demographic and Disease CharacteristicsData from 1,141 subjects with PV (N=519) and ET (N=622) was prospectively collected (Chinese 236, French 305, German 45, Italian 114, Dutch 191, English 56, Spanish 109, Swedish 85. Age (mean 59, range, 26-87) and gender (54% F) were typical. Five clusters were selected (Figure 1). Frequencies of prior bleeding, spleen size, anemia, presence of any lab abnormality, language, gender, and MPN type varied significantly between clusters (P[IMG]/small/bld0211200860128.gif" ALT="Figure 1">[IMG]/small/bld0211200860129.gif" ALT="Figure 1"> Figure 1. Individual symptom means by cluster. DisclosuresKiladjian: Celgene: Research Funding; Novartis: Honoraria, Research Funding; Shire: Honoraria. Roy: Novartis, BMS: Speakers Bureau. Harrison: Novartis: Honoraria, Research Funding, Speakers Bureau; YM Bioscience: Consultancy, Honoraria; Sanofi Aventis: Honoraria; Shire: Honoraria, Research Funding. Vannucchi: Novartis: Membership on an entity's Board of Directors or advisory committees. Passamonti: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Mesa: Incyte: Research Funding; Lilly: Research Funding; Sanofi: Research Funding; NS Pharma: Research Funding; YM Bioscience: Research Funding.\n
AB - Abstract 1726 BackgroundWe previously reported that symptom burden among persons with ET and PV can be severe and adversely affect QOL. The presence of severe symptoms is linked to poor prognosis. There is considerable inter-subject heterogeneity regarding which symptoms are present in which subjects. No studies have empirically evaluated whether disease characteristics can be grouped in related symptom clusters. Using our previously validated 18 item Myeloproliferative Neoplasm Assessment Form (MPN-SAF) (Blood 2011;118:401-408) given in conjunction with the 9 item Brief Fatigue Inventory (BFI) (Cancer 1999;85:1186-1196), we sought to evaluate symptom burden by means of cluster analysis. MethodsData was collected from an international cohort of subjects with MPNs including demographics, disease features and the completed BFI and MPN-SAF instruments. Surveyed symptoms included fatigue, early satiety, abdominal pain and discomfort, inactivity, headaches, concentration, dizziness, extremity tingling, insomnia, sexual difficulties, mood changes, cough, night sweats, pruritus, bone pain and fever on a 0 (absent) to 10 (worst-imaginable) scale. Development of symptom clusters was based on consideration of r-squared in hierarchical clustering using Ward linkage. Final cluster assignment was based on the nonhierarchical k-means method. Comparisons between symptom clusters were based on ANOVA and chi-squared tests. ResultsSubject Demographic and Disease CharacteristicsData from 1,141 subjects with PV (N=519) and ET (N=622) was prospectively collected (Chinese 236, French 305, German 45, Italian 114, Dutch 191, English 56, Spanish 109, Swedish 85. Age (mean 59, range, 26-87) and gender (54% F) were typical. Five clusters were selected (Figure 1). Frequencies of prior bleeding, spleen size, anemia, presence of any lab abnormality, language, gender, and MPN type varied significantly between clusters (P[IMG]/small/bld0211200860128.gif" ALT="Figure 1">[IMG]/small/bld0211200860129.gif" ALT="Figure 1"> Figure 1. Individual symptom means by cluster. DisclosuresKiladjian: Celgene: Research Funding; Novartis: Honoraria, Research Funding; Shire: Honoraria. Roy: Novartis, BMS: Speakers Bureau. Harrison: Novartis: Honoraria, Research Funding, Speakers Bureau; YM Bioscience: Consultancy, Honoraria; Sanofi Aventis: Honoraria; Shire: Honoraria, Research Funding. Vannucchi: Novartis: Membership on an entity's Board of Directors or advisory committees. Passamonti: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Mesa: Incyte: Research Funding; Lilly: Research Funding; Sanofi: Research Funding; NS Pharma: Research Funding; YM Bioscience: Research Funding.\n
M3 - Article
VL - 120
SP - 1726
JO - Blood (ASH Annual Meeting Abstracts)
JF - Blood (ASH Annual Meeting Abstracts)
IS - 21
ER -